LY2603618: Unveiling New Frontiers in Chk1 Inhibition and...
2025-10-21
Explore how LY2603618, a selective Chk1 inhibitor, is revolutionizing research into DNA damage response and genome stability. This article uniquely integrates emerging insights on nuclear cGAS, L1 retrotransposition, and cancer therapy sensitization.